Compounded GLP-1 Statistics 2026 | FDA Crackdown & What Changed Compounded GLP-1 Statistics 2026: The FDA Crackdown, Safety Data & What Changed Compounded semaglutide and tirzepatide access has changed dramatically since the shortages ended
The HR for prostate cancer among GLP-1RA users vs basal insulin users was 0.91 (95% CI 0.73, 1.14) in the ITT analysis and 0.80 (95% CI 0.64, 1.01) in the per-protocol analysis (Table 2)
The trial included 125 participants who were overweight or obese, receiving Amycretin via subcutaneous injection once weekly over varying durations
Polyethylene glycol 3350 (PEG 3350, brand name MiraLAX) is particularly well-suited due to its gentle mechanism, predictable effect, and minimal systemic absorption
Rizzo agreed that the association of NAION with a drug that is anti-inflammatory, neuroprotective and vasculoprotective is problematic, noting that at present there is no substantive basis for explaining the link between semaglutide and NAION